Parkman Healthcare Partners LLC Has $9.14 Million Stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Parkman Healthcare Partners LLC raised its stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 34.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 625,749 shares of the company’s stock after purchasing an additional 159,341 shares during the period. Day One Biopharmaceuticals makes up approximately 1.3% of Parkman Healthcare Partners LLC’s portfolio, making the stock its 26th biggest holding. Parkman Healthcare Partners LLC owned about 0.72% of Day One Biopharmaceuticals worth $9,136,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in DAWN. Arizona State Retirement System boosted its stake in shares of Day One Biopharmaceuticals by 8.2% in the 4th quarter. Arizona State Retirement System now owns 13,373 shares of the company’s stock worth $195,000 after buying an additional 1,010 shares during the last quarter. Principal Financial Group Inc. lifted its stake in Day One Biopharmaceuticals by 9.7% in the third quarter. Principal Financial Group Inc. now owns 17,781 shares of the company’s stock valued at $218,000 after purchasing an additional 1,569 shares during the last quarter. Alps Advisors Inc. lifted its stake in Day One Biopharmaceuticals by 2.5% in the third quarter. Alps Advisors Inc. now owns 64,153 shares of the company’s stock valued at $787,000 after purchasing an additional 1,592 shares during the last quarter. Quest Partners LLC purchased a new position in Day One Biopharmaceuticals in the fourth quarter valued at approximately $29,000. Finally, Amalgamated Bank lifted its stake in Day One Biopharmaceuticals by 35.7% in the third quarter. Amalgamated Bank now owns 8,628 shares of the company’s stock valued at $106,000 after purchasing an additional 2,268 shares during the last quarter. Institutional investors and hedge funds own 87.95% of the company’s stock.

Day One Biopharmaceuticals Trading Down 0.6 %

Shares of Day One Biopharmaceuticals stock traded down $0.08 during trading on Thursday, hitting $12.92. The stock had a trading volume of 666,519 shares, compared to its average volume of 869,737. The firm has a market cap of $1.13 billion, a price-to-earnings ratio of -5.15 and a beta of -1.53. Day One Biopharmaceuticals, Inc. has a 12 month low of $9.67 and a 12 month high of $18.07. The business’s 50-day moving average is $14.82 and its 200 day moving average is $14.65.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its earnings results on Monday, May 6th. The company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.05). As a group, equities analysts expect that Day One Biopharmaceuticals, Inc. will post -2.69 EPS for the current year.

Insider Activity at Day One Biopharmaceuticals

In related news, CFO Charles N. York II sold 52,183 shares of the stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $17.89, for a total value of $933,553.87. Following the transaction, the chief financial officer now owns 225,571 shares of the company’s stock, valued at $4,035,465.19. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Day One Biopharmaceuticals news, CEO Jeremy Bender sold 70,051 shares of the company’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $17.88, for a total transaction of $1,252,511.88. Following the completion of the sale, the chief executive officer now directly owns 651,762 shares in the company, valued at $11,653,504.56. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Charles N. York II sold 52,183 shares of the company’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $17.89, for a total transaction of $933,553.87. Following the sale, the chief financial officer now owns 225,571 shares of the company’s stock, valued at $4,035,465.19. The disclosure for this sale can be found here. Insiders have sold a total of 185,534 shares of company stock valued at $3,236,030 over the last 90 days. 8.40% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. Oppenheimer reiterated a “market perform” rating on shares of Day One Biopharmaceuticals in a research note on Tuesday, February 27th. Wedbush reissued an “outperform” rating and set a $33.00 target price on shares of Day One Biopharmaceuticals in a report on Tuesday, May 7th. Piper Sandler reissued an “overweight” rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a report on Tuesday, March 26th. The Goldman Sachs Group lowered their target price on shares of Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating on the stock in a report on Tuesday, February 27th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Day One Biopharmaceuticals from $32.00 to $36.00 and gave the company an “overweight” rating in a report on Monday, April 22nd. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, Day One Biopharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $37.67.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.